arenavirida
famili
virus
sever
member
caus
viral
hemorrhag
fever
acut
oftenfat
viral
syndrom
character
intens
fever
malais
less
frequent
bleed
neurolog
manifest
case
fatal
rate
hospit
patient
suffer
arenavir
hemorrhag
fever
ahf
rang
arenavirus
known
caus
ahf
includ
machupo
guanarito
chapar
south
american
contin
lassa
lujo
west
southern
africa
respect
primari
transmiss
arenavirus
respect
rodent
reservoir
host
human
occur
via
exposur
contamin
excreta
persontoperson
transmiss
occur
contact
blood
bodi
fluid
care
manag
infect
individu
notabl
virus
consid
threat
nation
secur
classifi
highest
prioriti
pathogen
niaid
present
treatment
ahf
limit
ribavirin
immun
plasma
latter
proven
effect
treat
case
argentin
hemorrhag
fever
viru
infect
within
day
diseas
onset
offlabel
usag
ribavirin
shown
effect
treat
lassa
fever
therapi
initi
within
day
develop
clinic
symptom
howev
toxic
associ
ribavirin
therapi
dosag
requir
efficaci
use
may
contribut
observ
poor
patient
complianc
complet
prescrib
treatment
regimen
limit
case
data
use
ribavirin
treat
ahf
support
use
emerg
protocol
howev
util
ribavirin
therapi
remain
seen
interferon
alpha
effect
part
host
innat
immun
respons
manufactur
recombin
human
protein
broad
clinic
appeal
consensu
c
also
known
ifn
infergen
licens
second
gener
engin
contain
frequent
occur
amino
acid
among
nonallel
subtyp
previous
demonstr
use
effect
alon
combin
ribavirin
treat
viru
picv
infect
hamster
experiment
model
acut
arenavir
diseas
howev
clinic
valu
use
hinder
short
halflif
cost
manufactur
initi
distribut
halflif
minut
beta
halflif
hour
rapid
system
clearanc
requir
frequent
dose
achiev
desir
therapeut
level
consequ
treatment
result
welldocu
toxic
includ
headach
depress
hair
loss
fever
malais
order
combat
rapid
degrad
pegyl
form
recombin
introduc
halfliv
order
day
instead
hour
thu
reduc
number
inject
per
week
howev
cost
manufactur
exceedingli
high
pegyl
process
shown
reduc
activ
therebi
increas
product
cost
circumv
fast
decay
replicationincompet
recombin
adenoviru
type
gene
deliveri
platform
design
drive
constitut
express
gene
transduc
nasal
epitheli
target
cell
viru
call
first
develop
mice
recent
shown
activ
yellow
fever
viru
yfv
infect
hamster
intranas
inocul
use
yfv
studi
prevent
host
immun
system
recogn
vector
therebi
bypass
possibl
preexist
immun
present
studi
evalu
use
administ
prevent
treatment
picv
infect
hamster
anim
procedur
compli
usda
guidelin
conduct
aaalacaccredit
laboratori
anim
research
center
utah
state
univers
protocol
approv
utah
state
univers
institut
anim
care
use
committe
femal
golden
syrian
hamster
obtain
charl
river
laboratori
wilmington
acclim
minimum
day
prior
experiment
fed
standard
hamster
chow
tap
water
ad
libitum
anim
approxim
week
old
time
viru
challeng
picv
strain
provid
dr
david
gangemi
clemson
univers
clemson
south
carolina
viru
passag
hamster
viru
stock
prepar
pool
liver
harvest
infect
hamster
viru
dilut
made
minim
essenti
medium
mem
infecti
inoculum
given
bilater
two
intraperiton
ip
inject
ml
recombin
adenoviru
vector
empti
vector
rad
ev
control
viru
provid
defyru
inc
toronto
canada
concentr
plaqueform
unit
pfu
ml
respect
virus
prepar
pb
instil
volum
viru
titer
assay
use
infecti
cell
cultur
assay
previous
describ
briefli
specif
volum
liver
spleen
homogen
serum
serial
dilut
ad
triplic
well
vero
african
green
monkey
kidney
american
type
cultur
collect
manassa
va
cell
monolay
micropl
viral
cytopath
effect
cpe
determin
day
postviru
inocul
endpoint
calcul
describ
assay
detect
rang
cell
cultur
infecti
dose
g
liver
spleen
serum
sampl
present
undetect
liver
spleen
viru
valu
assign
serum
convers
case
wherein
viru
exceed
detect
rang
valu
serum
assign
statist
analysi
valu
serum
assign
need
sampl
undetect
satur
viru
level
respect
detect
alt
serum
indirect
method
evalu
liver
diseas
serum
alt
level
measur
use
alt
sgpt
reagent
set
purchas
point
scientif
inc
lincoln
park
mi
per
manufactur
recommend
reagent
volum
adjust
analysi
micropl
hamster
weigh
morn
prior
day
infect
group
n
drug
treatment
group
placebo
group
averag
hamster
weight
per
group
across
entir
experi
vari
less
gram
vari
pfu
amount
rad
ev
control
viru
salin
placebo
treatment
administ
singl
dose
h
prior
challeng
pfu
picv
five
anim
group
sacrif
day
infect
serum
collect
assay
alt
activ
viru
titer
determin
liver
spleen
serum
sampl
describ
remain
anim
placebo
group
observ
day
mortal
weigh
individu
everi
day
start
day
shaminfect
normal
control
n
includ
comparison
design
similar
titrat
experi
follow
differ
hamster
weigh
morn
initi
pretreat
day
rel
infect
group
n
per
group
group
treat
pfu
rad
ev
control
viru
salin
placebo
treatment
given
day
prior
challeng
pfu
picv
anim
observ
day
postchalleng
mortal
design
similar
preexposur
prophylaxi
experi
follow
differ
singl
dose
treatment
pfu
rad
ev
administ
h
prior
h
challeng
pfu
picv
day
postinfect
surviv
anim
includ
shaminfect
control
rechalleng
morbid
mortal
observ
day
initi
challeng
kaplanmei
surviv
plot
statist
evalu
done
use
prism
graphpad
softwar
ca
logrank
test
use
surviv
analysi
analyz
differ
viral
titer
alt
level
weight
chang
oneway
analysi
varianc
anova
newmankeul
post
test
kruskalw
twotail
test
dunn
post
test
perform
base
gaussian
distribut
data
initi
trial
hamster
treat
pfu
one
day
prior
challeng
lethal
dose
picv
pretreat
highest
dose
pfu
result
surviv
pfu
dose
also
significantli
protect
hamster
respect
mortal
figur
moreov
hamster
succumb
group
surviv
day
importantli
one
ten
hamster
treat
pfu
control
rad
ev
viru
surviv
infect
howev
appear
slight
delay
time
death
hamster
receiv
control
viru
treatment
weight
hamster
measur
everi
day
assess
weight
gain
cours
experi
marker
well
figur
notabl
day
day
time
weight
loss
due
ill
picv
infect
would
expect
hamster
weight
decreas
dose
increas
would
suggest
higher
treatment
dose
may
result
loss
appetit
probabl
due
mild
ill
due
express
consensu
ifn
sinc
overt
effect
notic
handl
anim
hamster
receiv
pfu
dose
gain
weight
day
similarli
anim
treat
salin
placebo
normal
control
shaminfect
untreat
figur
highdos
rad
ev
control
viru
also
result
slight
reduct
weight
compar
control
suggest
immun
respons
adenovir
vector
alon
may
caus
malais
anim
elev
serum
alt
level
day
infect
sampl
collect
parallel
treat
infect
hamster
receiv
figur
eighti
percent
rad
ev
group
pb
placebo
group
elev
level
alt
reflect
liver
diseas
interestingli
pfu
group
present
littl
viru
burden
serum
liver
spleen
group
develop
viral
titer
compar
rad
ev
placebo
control
figur
delay
develop
liver
diseas
pfu
anim
may
explain
reduc
alt
level
altern
satur
liver
viru
titer
lowdos
rad
ev
placebo
group
may
mask
substanti
differ
former
viral
vector
vehicl
control
group
next
evalu
prophylact
window
protect
picv
infect
use
pfu
dose
anim
treat
one
two
week
prior
challeng
lethal
dose
picv
consist
trend
observ
initi
dose
titrat
studi
hamster
treat
pfu
dose
significantli
reduc
weight
compar
receiv
rad
ev
placebo
control
treatment
figur
nevertheless
pretreat
seven
day
infect
highli
protect
surviv
rate
figur
notabl
singl
hamster
fail
surviv
challeng
succumb
day
sever
day
mean
time
death
measur
placebo
rad
ev
group
autopsi
determin
caus
death
perform
hamster
treat
twoweek
prior
picv
challeng
significantli
reduc
mortal
surviv
extend
time
death
anim
succumb
figur
contrast
uniform
lethal
seen
anim
receiv
rad
ev
placebo
treatment
surviv
anim
pretreat
one
anorex
conclus
studi
day
postinfect
reflect
weight
loss
compar
anim
start
weight
possibl
hamster
appear
ill
letharg
abl
complet
prevent
infect
unclear
whether
would
ultim
recov
observ
period
extend
figur
c
e
g
figur
f
h
pretreat
significantli
reduc
viral
load
liver
diseas
alt
compar
control
absenc
elev
alt
level
hamster
may
explain
reduct
liver
viru
burden
figur
f
delay
develop
liver
diseas
although
tissu
titer
slightli
lower
given
day
prior
challeng
compar
day
pretreat
evid
serum
viral
burden
anim
measur
replic
picv
figur
like
survivor
would
immun
protect
subsequ
challeng
may
case
hamster
treat
h
prior
challeng
sinc
detect
viru
titer
spleen
liver
serum
day
picv
infect
figur
observ
dramat
protect
administ
week
prior
challeng
final
experi
conduct
determin
therapeut
valu
hamster
picv
infect
model
administ
h
challeng
highli
signific
protect
observ
figur
efficaci
wane
treatment
delay
h
postinfect
anticip
treatment
given
prechalleng
verifi
previou
activ
anim
surviv
challeng
interestingli
higher
expect
surviv
control
rad
ev
treatment
initi
h
postchalleng
suggest
slight
antivir
effect
time
treatment
delay
figur
surviv
hamster
experi
rechalleng
picv
assess
abil
enhanc
longerterm
protect
via
acquir
immun
except
anim
h
pretreat
group
singl
anim
rad
ev
h
group
anim
challeng
picv
day
experi
surviv
second
challeng
day
figur
six
anim
initi
shaminfect
succumb
expect
anim
sacrif
day
rel
first
infect
reduct
alt
viral
titer
evid
group
receiv
within
h
infect
figur
notabl
anim
treat
control
rad
ev
interest
trend
develop
h
postinfect
group
greatest
alt
level
viral
titer
follow
h
group
trend
may
suggest
lowlevel
immun
stimul
hamster
rel
time
rad
ev
given
result
lack
measur
viral
replic
h
group
figur
like
insuffici
elicit
immunolog
memori
unclear
one
first
infect
survivor
h
rad
ev
group
ultim
succumb
second
infect
present
studi
find
demonstr
express
follow
singl
administr
offer
strong
protect
effect
hamster
challeng
picv
includ
limit
liver
diseas
induc
antivir
state
inhibit
system
tissu
viral
replic
lack
signific
antivir
activ
elicit
rad
ev
control
viru
suggest
enhanc
antivir
respons
produc
larg
due
express
gene
weak
stimulatori
effect
seen
experi
surpris
consid
number
host
system
play
role
sens
adenoviru
vector
howev
effect
shortliv
contrast
enhanc
host
antivir
defens
longlast
prepicv
challeng
prophylact
window
moreov
effect
given
day
postpicv
infect
data
also
suggest
suffici
viral
replic
may
necessari
elicit
adapt
immun
respons
confer
last
protect
immun
part
rechalleng
anim
h
pretreat
group
succumb
second
challeng
lethal
picv
inoculum
presum
robust
innat
immun
antivir
state
induc
pretreat
rapidli
control
pfu
challeng
dose
obviat
develop
adapt
immun
respons
immunolog
memori
pathogen
arenavirus
evolv
strategi
suppress
evad
host
immun
respons
result
uncontrol
replic
broad
dissemin
howev
appear
unabl
block
induct
ifn
stimul
gene
via
exogen
type
ifn
may
part
explain
success
treatment
also
essenti
success
earli
intervent
prior
signific
viral
replic
engag
innat
immun
suppress
function
inde
earli
induct
strong
type
ifn
respons
associ
favor
diseas
outcom
nonhuman
primat
challeng
lassa
viru
earli
postexposur
prophylaxi
also
requir
exogen
protein
administ
ip
rout
multipl
strategi
arena
pathogen
virus
place
subdu
ifnmedi
host
antivir
respons
util
recombin
ifn
protein
ifn
induc
agent
depend
upon
natur
ifn
pathway
blockad
requir
earli
administr
effect
postexposur
notabl
daili
protein
inject
signific
protect
observ
howev
surviv
rate
exceed
studi
employ
picv
hamster
model
system
viru
stock
contrast
consist
elicit
greater
protect
improv
efficaci
observ
may
explain
combin
factor
includ
constitut
express
fulli
glycosyl
protein
reduc
anim
stress
level
avoid
daili
inject
day
hypothes
appropri
dose
therapeut
level
consensu
maintain
effect
elimin
daili
bolu
effect
produc
ip
inject
addit
produc
genet
engin
escherichia
coli
nativ
glycosyl
pattern
lost
conceiv
enhanc
immunotherapeut
activ
result
fulli
glycosyl
express
cell
transduc
previou
studi
mice
relat
viru
express
mous
shown
util
adenovirusbas
system
counter
viral
infect
recent
differ
hamster
model
viral
hemorrhag
fever
sever
us
report
efficaci
mitig
yfv
infect
diseas
yfv
infect
appear
sensit
effect
lower
dose
abl
provid
complet
protect
taken
togeth
result
present
studi
experiment
anim
data
support
broad
use
extend
preexposur
earli
postexposur
prophylaxi
applic
investig
use
advanc
arenaviru
model
base
challeng
nonhuman
primat
pathogen
arenavirus
need
better
evalu
potenti
prevent
sever
diseas
human
nonhuman
primat
model
allow
full
spectrum
activ
possibl
hamster
guinea
pig
familiar
fda
adenoviru
gene
deliveri
technolog
approv
protein
support
develop
clinic
use
import
step
develop
process
safetytoxicolog
test
rodent
present
underway
studi
highest
dose
pfu
administ
rout
appear
welltoler
hamster
despit
evid
weight
loss
appear
visibl
ill
clearli
treatment
effect
possibl
led
reduc
food
water
consumpt
consist
mild
toxic
seen
therapi
deliveri
rout
design
circumv
preexist
immun
adenoviru
type
human
may
limit
system
inflamm
could
occur
parenter
administr
larg
number
adenoviru
particl
ultim
product
shelfstabl
powder
formul
easi
administr
longterm
storag
would
ideal
stockpil
event
need
mass
distribut
due
intent
releas
emerg
diseas
outbreak
arena
viral
etiolog
